Metrics to compare | FBLG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFBLGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −7.2x | −0.4x | |
PEG Ratio | −0.02 | −0.90 | 0.00 | |
Price/Book | 2.3x | 4.3x | 2.6x | |
Price / LTM Sales | - | 16.7x | 3.0x | |
Upside (Analyst Target) | - | 72.4% | 55.1% | |
Fair Value Upside | Unlock | 7.4% | 8.2% | Unlock |
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.